ClinicalTrials.gg
CompletedNCT01584492PAED3Updated Mar 29, 2017

Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children

A Phase 2 interventional study of beclomethasone+formoterol 50/6 (1 inhalation) and CHF 1535 50/6 (2 inhalations) in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 2 sites in 2 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Enrollment
44th of 66
59 · median 97
Started
2011
with 7 others
Phase 2
25 of 81
1 open now
Registered
30th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 44th largest by enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2011, is one of 25 in phase 2, and was the 30th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The purpose of this clinical study is to compare the improvement in breathing of single administration of CHF 1535 50/6 pMDI (fixed combination of a corticosteroid drug beclomethasone 50 µg + formoterol 6 µg/puff, 2 inhalations, total dose 100/12 µg) given with spacer versus free combination of beclomethasone 50 µg/puff pMDI (2 inhalations, total dose 100 µg) given with spacer plus formoterol 6 µg/puff pMDI (2 inhalations, total dose 12 µg) given with spacer in terms of FEV1 from 0 to 12 hours in asthmatic children.

Additionally the study aims to evaluate the effects of doses of CHF 1535 pMDI compared to placebo and the effect on other lung function parameters, to assess the safety and tolerability of CHF 1535 dosages in children.

Read the detailed description

FEV1 from 0 to 12 hours standardised by time will be statistically analysed taking into account treatment, period and subject and pre-dose FEV1.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from the parents/legal representatives and/or the subject (if and when appropriate)
  • Prepuberal male and female outpatients, aged ≥ 5 and \< 12 years (Tanner stage I and II)
  • Clinical diagnosis of asthma according to Global Strategy for Asthma Management and Prevention (GINA) revised version 2009 at least six months prior to screening visit.
  • Already treated with inhaled short acting Beta2-agonists as required and / or inhaled beclomethasone dipropionate up to 400 µg or equivalent.
  • Forced Expiratory Volume during the first second () ≥ 60% and ≤ 95% of predicted normal values at the screening visit.
  • A documented positive response to the reversibility test at the screening visit, defined as Delta FEV1 ≥ 15% over baseline, 15 minutes after 400 μg salbutamol pressurised Meter Dose Inhaler (ATS/ERS taskforce 2005).
  • A cooperative attitude and ability to use a pMDI and a spacer (Aerochamber Plus and Volumatic).

Exclusion criteria

Exclusion Criteria:

  • Endocrinological diseases or other chronic diseases.
  • Known sensitivity to the components of study medication.
  • Any concomitant disease requiring additional treatment with topic or systemic glucocorticosteroids.
  • Allergy to one component of medications used.
  • Intolerance or to treatment with Beta2-agonists and/or inhaled .
  • Having received an drug within 2 months before the current study.
  • Inability to comply to study procedures or to study treatment intake.
  • Occurrence of acute asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening visit.
  • Significant seasonal variation in asthma or asthma occurring only during episodic exposure to an allergen or a chemical sensitizer.
  • History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency.
  • History of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma exacerbation in Intensive Care Unit).
  • Diagnosis of restrictive lung disease.
  • Significant medical history and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, or any laboratory abnormality indicative of a significant underlying condition, that may interfere with patient's safety, compliance, or study evaluations, according to the investigator's opinion.
  • (Fridericia's formula) higher than 450 msec at screening visit
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Treatment A

    CHF 1535 50/6 administered via a pMDI with spacer, 1 inhalation (dose: BDP 50 µg/FF 6 µg) + placebo HFA pMDI with spacer, 5 inhalations in the morning at the clinic

    Drug: beclomethasone+formoterol 50/6 (1 inhalation)

  • Experimental
    Treatment B:

    CHF 1535 50/6 administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg/FF 12 µg) + placebo HFA pMDI with spacer, 4 inhalations in the morning at the clinic

    Drug: CHF 1535 50/6 (2 inhalations)

  • Experimental
    Treatment C

    CHF 1535 50/6 (dose: BDP 200 µg/FF 24 µg) administered via a pMDI with spacer, 4 inhalations (dose: BDP 200 µg/FF 24 µg) in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic

    Drug: CHF 1535 50/6 (4 inhalations)

  • Active comparator
    Treatment D

    formoterol 6 µg HFA administered via a pMDI with spacer, 2 inhalations (dose: FF 12 µg) + extrafine BDP 50 µg, administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg), in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic

    Drug: Formoterol + Beclomethasone dipropionate

  • Placebo comparator
    Treatment E

    placebo pMDI with spacer, 6 inhalations in the morning at the clinic

    Drug: Placebo (6 inhalations)

Interventions

  • Drugbeclomethasone+formoterol 50/6 (1 inhalation)

    CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer

    Also known as: CHF1535, Atimos®, Ventolair®, Ventolin®

  • DrugCHF 1535 50/6 (2 inhalations)

    CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer

    Also known as: CHF1535, Atimos®, Ventolair®, Ventolin®

  • DrugCHF 1535 50/6 (4 inhalations)

    CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer

    Also known as: CHF1535, Atimos®, Ventolair®, Ventolin®

  • DrugFormoterol + Beclomethasone dipropionate

    Drug pages: Formoterol · Beclomethasone

    * Formoterol HFA pMDI 6 µg / actuation * Extrafine BDP HFA pMDI 50 µg/actuation

    Also known as: CHF1535, Atimos®, Ventolair®, Ventolin®

  • DrugPlacebo (6 inhalations)

    Matched placebo via pMDI

    Also known as: CHF1535, Atimos®, Ventolair®, Ventolin®

06

What researchers measure

Primary outcomes

  1. bronchodilator effect of test treatment

    To compare the bronchodilator effect of single administration of CHF 1535 50/6 pMDI (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose, 2 inhalations, total dose 100/12 µg) given with spacer vs. free combination of extrafine beclomethasone dipropionate 50 µg/metered dose pMDI (2 inhalations, total dose 100 µg) given with spacer plus formoterol 6 µg/metered dose pMDI (2 inhalations, total dose 12 µg) given with spacer in terms of FEV1 AUC 0-12 hours corrected by time for the 12 hours study period in asthmatic children.

    Time frame: FEV1 AUC measured over 12 hours

Secondary outcomes

  1. dose-related effects of test treatment

    To evaluate the dose-related effects of CHF 1535 pMDI compared to placebo and the effect on other lung function parameters, to assess the safety and tolerability of CHF 1535 regimens in children.

    Time frame: Peak FEV1 and FEV1 measured at 12 hours post-dose

07

Study locations

2 sites
  • Poradnia Alergologiczna
    Debica, Debica, Poland 39 -200, Poland
  • Zaporizhzhia State Medical University
    Zaporizhzhia, 69063, Ukraine
08

References and documents

Publications

  • Pohunek P, Varoli G, Reznichenko Y, Mokia-Serbina S, Brzostek J, Kostromina V, Kaladze M, Muraro A, Carzana E, Armani S, Kaczmarek J. Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study. Eur J Pediatr. 2021 May;180(5):1467-1475. doi: 10.1007/s00431-020-03888-x. Epub 2021 Jan 6. PubMed 33404895 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2012
First posted
Apr 25, 2012
Start
Dec 2011
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01584492
Responsible party
Sponsor
First posted
Apr 25, 2012
Start date
Dec 2011
Primary completion
Feb 2013
Completion
Feb 2013
Last update
Mar 29, 2017

Study contacts

Petr Pohunek, M.D.
principal investigator · Charles University, 2nd Medical Faculty and University Hospital Motol - CZECH REPUBLIC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion